Piperazine Erastin |
| Catalog No.GC36926 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1538593-71-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Piperazine erastin is an analog of erastin which induces an iron-dependent form of non-apoptotic cell death, termed ferroptosis.
Erastin is a ferroptosis activator. It triggers a unique iron-dependent form of non-apoptotic cell death that is termed as ferroptosis. Piperazine erastin is a more effective analog of erastin which is more water-soluble (0.086 mM for erastin versus 1.4 mM for piperazine erastin) and more metabolically stable. Piperazine erastin is affected similarly by cell death modulators as erastin and displays a distinct pattern from other non-FIN lethal compounds[1].
In the xenograft mouse model, a significant delay in tumor growth is observed in the piperazine erastin-treated group compared to the vehicle-treated group. Ptgs2 is upregulated in mouse liver with 10 or 60 mg/kg piperazine erastin administration[1].
[1]. Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014 Jan 16;156(1-2):317-331.
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *